BHST

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facilityMilestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercializationHigh-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across liver steatosis and fibrosis models, with potential for development across multiple health and wellness categoriesVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - Oc

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solutionVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ:BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme.The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.This achievement marks continued positive prog

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practices as a normal course issuer bid (the "NCIB"). The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects. Conseque

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, in New York City, NY. In addition to presenting, Dr. Rakib will also participate in one-on-one investor meetings throughout the conference.CEO Zaki Rakib commented "We have recently announced several major advancements in our CDMO research and development programs, which includes

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.Dr Zaki Rakib, CEO of BioHarvest Sciences, commented, "BioHarvest is entering an exciting new phase of growth, built on the strength of our Botanical Synthesis platform and the commercial opportunities it is creating.

Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO businessReports $8.8 million in Q2 revenue, up 3.8% from Q2 2025Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced results from the second quarter and six months of 2026. Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "We are extremely pleased to have announced a man

Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenuePositions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional collaborations in the high-margin rare fragrance space Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced an exclusive manufacturing and supply agreement that secures production of a rare, endangered, fragrance plant cell culture, extending terms of the original Agreement ("the Agreement") with its existin

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In addition to presenting, Dr. Rakib will also be participating in one-on-one investor meetings from August 11-12.Presentation Details:Date/Time: Wednesday, August 12, 2026, at 1:00 p.m. ETPresenter: Zaki Rakib, Chief Executive OfficerFormat: Company PresentationIn Person

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide an update on business operations."As I approach my first 100 days as CEO, I look forward to presenting our second quarter results and providing additional insights into our 2026 strategy and grow

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest's CDMO customers and partnersVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learnin

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.Presentation Details:Date/Time: Wednesday, July 22, 2026 at 10:00 a.m. ETPresenter: Zaki Rakib, Chief Executive OfficerFormat: Fireside Chat Location: VirtualOnline Access: https://digital.maximgrp.com/signupIn this virtual conference, Maxim Group Research Analysts sit dow

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details:Session: Company PresentationDate/Time: Wednesday, June 24, 11:45 AMLocation: Theater 3BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability,

6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.The expanded collaboration